MedTrace Logo

Rituximab in Treating Patients With Hodgkin's Lymphoma

NCT00003820 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2017-04-20

Study results available
· View outcomes & findings →

Summary

Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.

Conditions

  • Lymphoma
  • Hodgkin Lymphoma (Category)
  • Nodular Lymphocyte Predominant Hodgkin Lymphoma

Interventions

DRUG

Rituximab

Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Ranjana Advani

    lead OTHER

Principal Investigators

  • Ranjana H Advani, MD · Stanford University

  • Richard T Hoppe, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31
Primary Completion
2008-08-31
Completion
2008-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003820 on ClinicalTrials.gov